M. Drayson

ZOLEDRONIC ACID (ZOL) SIGNIFICANTLY REDUCES SKELETAL-RELATED EVENTS (SRES) VERSUS CLODRONATE (CLO) IN PATIENTS (PTS) WITH MULTIPLE MYELOMA (MM): RESULTS OF THE MEDICAL RESEARCH COUNCIL (MRC) MYELOMA IX STUDY

G. Morgan, G. Jackson, S. Bell, 2010 .

Effect of feeding different amounts of carbohydrate during prolonged exercise on human T-lymphocyte intracellular cytokine production

A. Jeukendrup, M. Gleeson, M. Drayson, 2003 .

High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment.

E Roman, J A Child, G. Morgan, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The behavior of autologous indium-114m-labeled lymphocytes in patients with lymphoid cell malignancy.

D. Deakin, R. Cowan, D. Crowther, 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Does zoledronic acid (ZOL) reduce skeletal-related events (SREs) and improve progression-free survival (PFS) in patients (Pts) with multiple myeloma (MM) with or without bone disease? MRC myeloma IX study results.

G. Cook, J. Byrne, F. Ross, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Are there benefits to long-term bisphosphonate treatment in multiple myeloma (MM)? Insights from temporal analyses of zoledronic acid (ZOL) versus clodronate (CLO) in the MRC Myeloma IX Trial.

G. Cook, J. Byrne, F. Ross, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Secondary Adrenal Failure in a Young Woman Presenting as Hypoglycaemic Coma

L. McWilliam, I. Laing, M. Drayson, 1998, Annals of clinical biochemistry.